Review





Similar Products

96
Miltenyi Biotec cd45 viogreen
Cd45 Viogreen, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd45+antibody/CD45+Antibody%2C+anti-human%2C+REAfinity/pm42985785-64-23-38
Average 96 stars, based on 1 article reviews
cd45 viogreen - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

97
Miltenyi Biotec anti cd45 microbeads
Anti Cd45 Microbeads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd45+antibody/CD45+MicroBeads%2C+mouse/pm43003077-839-185-187
Average 97 stars, based on 1 article reviews
anti cd45 microbeads - by Bioz Stars, 2026-11
97/100 stars
  Buy from Supplier

96
Elabscience Biotechnology anti cd45 percp cy5 5
Anti Cd45 Percp Cy5 5, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd45+antibody/PerCP/pm43000390-109-6-7
Average 96 stars, based on 1 article reviews
anti cd45 percp cy5 5 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

93
Novus Biologicals dylight 650 conjugated anti cd45
Therapeutic effects on inflammatory cell infiltration. ( A ) Representative OCT images of the anterior chamber 10 days post-alkali burn, including healthy, alkali burn only (untreated), and treatment with aflibercept or anti–Scg3 hAb, respectively. ( B ) H&E images showing leukocyte infiltration ( red arrows ) in the corneas, day 10 post-injury ( n = 3 corneas). ( C , D ) Images showing flow cytometry data ( C ) and quantification of <t>CD45</t> + cells ( D ) on day 3 after alkali burn ( n = 3 samples per group; 5 corneas pooled per sample). ( E , F ) Immunofluorescence images of corneas stained with <t>anti-CD45</t> ( E ), and the quantified number of CD45 + cells ( F ) ( n = 3 corneas). Scale bar : 50 µm. ( G , H ) Graphs showing mRNA expression of IL-1α ( G ) and TGF-β ( H ) ( n = 3 samples per group; 5 corneas pooled per sample). Data are presented as ±SEM. P < 0.05 (one-way ANOVA).
Dylight 650 Conjugated Anti Cd45, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd45+antibody/CD45+Antibody+(30-F11)+-+BSA+Free/pmc13760287-47-30-37
Average 93 stars, based on 1 article reviews
dylight 650 conjugated anti cd45 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
Novus Biologicals anti mouse cd45 af 647 em 05
Therapeutic effects on inflammatory cell infiltration. ( A ) Representative OCT images of the anterior chamber 10 days post-alkali burn, including healthy, alkali burn only (untreated), and treatment with aflibercept or anti–Scg3 hAb, respectively. ( B ) H&E images showing leukocyte infiltration ( red arrows ) in the corneas, day 10 post-injury ( n = 3 corneas). ( C , D ) Images showing flow cytometry data ( C ) and quantification of <t>CD45</t> + cells ( D ) on day 3 after alkali burn ( n = 3 samples per group; 5 corneas pooled per sample). ( E , F ) Immunofluorescence images of corneas stained with <t>anti-CD45</t> ( E ), and the quantified number of CD45 + cells ( F ) ( n = 3 corneas). Scale bar : 50 µm. ( G , H ) Graphs showing mRNA expression of IL-1α ( G ) and TGF-β ( H ) ( n = 3 samples per group; 5 corneas pooled per sample). Data are presented as ±SEM. P < 0.05 (one-way ANOVA).
Anti Mouse Cd45 Af 647 Em 05, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd45+antibody/CD45+Antibody+(EM-05)+%5BAlexa+Fluor%C2%AE+647%5D/pm42982037-856-70-75
Average 94 stars, based on 1 article reviews
anti mouse cd45 af 647 em 05 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Miltenyi Biotec anti cd45 2
Therapeutic effects on inflammatory cell infiltration. ( A ) Representative OCT images of the anterior chamber 10 days post-alkali burn, including healthy, alkali burn only (untreated), and treatment with aflibercept or anti–Scg3 hAb, respectively. ( B ) H&E images showing leukocyte infiltration ( red arrows ) in the corneas, day 10 post-injury ( n = 3 corneas). ( C , D ) Images showing flow cytometry data ( C ) and quantification of <t>CD45</t> + cells ( D ) on day 3 after alkali burn ( n = 3 samples per group; 5 corneas pooled per sample). ( E , F ) Immunofluorescence images of corneas stained with <t>anti-CD45</t> ( E ), and the quantified number of CD45 + cells ( F ) ( n = 3 corneas). Scale bar : 50 µm. ( G , H ) Graphs showing mRNA expression of IL-1α ( G ) and TGF-β ( H ) ( n = 3 samples per group; 5 corneas pooled per sample). Data are presented as ±SEM. P < 0.05 (one-way ANOVA).
Anti Cd45 2, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd45+antibody/CD45%2E2+Antibody%2C+anti-mouse/bio_rxiv__64898__2026__11__03__763975-67-27-28
Average 94 stars, based on 1 article reviews
anti cd45 2 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc rabbit monoclonal anti cd45
Therapeutic effects on inflammatory cell infiltration. ( A ) Representative OCT images of the anterior chamber 10 days post-alkali burn, including healthy, alkali burn only (untreated), and treatment with aflibercept or anti–Scg3 hAb, respectively. ( B ) H&E images showing leukocyte infiltration ( red arrows ) in the corneas, day 10 post-injury ( n = 3 corneas). ( C , D ) Images showing flow cytometry data ( C ) and quantification of <t>CD45</t> + cells ( D ) on day 3 after alkali burn ( n = 3 samples per group; 5 corneas pooled per sample). ( E , F ) Immunofluorescence images of corneas stained with <t>anti-CD45</t> ( E ), and the quantified number of CD45 + cells ( F ) ( n = 3 corneas). Scale bar : 50 µm. ( G , H ) Graphs showing mRNA expression of IL-1α ( G ) and TGF-β ( H ) ( n = 3 samples per group; 5 corneas pooled per sample). Data are presented as ±SEM. P < 0.05 (one-way ANOVA).
Rabbit Monoclonal Anti Cd45, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd45+antibody/CD45+Rabbit+mAb/pm42981186-194-238-241
Average 96 stars, based on 1 article reviews
rabbit monoclonal anti cd45 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

94
Elabscience Biotechnology cd45
Combination therapy activates innate immunity via the STING-TBK1-IRF3-IFNβ pathway and enhances T-cell function. (A) Western blot analysis of STING pathway components (TBK1, p-TBK1, p-IRF3, IFNβ, NF-κB) in H82R and H526R cells. (B) Schematic illustration of the multicellular tumor spheroid (MCT) model composed of H82R SCLC cells, MRC-5 fibroblasts, HUVECs, and PBMCs. (C) Representative bright-field images of MCTs after treatment. Scale bar, 100 μm. (D) Flow cytometry analysis of CD8 + cytotoxic T cells, CD4 + helper T cells, and <t>CD45</t> + HLA-DR + activated immune cells in MCTs (left) and quantification of cell percentages (right). All experiments were performed independently three times. n = 3 biologically independent replicates. The Student’s t-test was used to estimate the significance of the difference between two groups. Comparisons among multiple groups were performed by one-way ANOVA followed by Tukey’s post hoc test. Data were presented as means ± s.d. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant.
Cd45, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd45+antibody/PerCP+Anti-Human+CD45+Antibody/pmc13774206-48-21-23
Average 94 stars, based on 1 article reviews
cd45 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

96
Miltenyi Biotec antibodies against human cd45
a. Leukemic burden in T-ALL PDX1 mice, measured as the percentage of <t>human</t> <t>CD45-positive</t> (hCD45⁺) cells in peripheral blood during treatment with ASNase (25 IU/mouse every 8 days) for 5 weeks. Treatment was discontinued following sacrifice of the vehicle-treated mice, and the remaining mice were monitored until reaching the experimental endpoint. Each dot represents an individual mouse. b. Bodyweight of mice shown in , expressed as the percentage of baseline bodyweight. Dots represent group means; error bars indicate SEM.
Antibodies Against Human Cd45, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd45+antibody/CD45+Antibody%2C+anti-human%2C+REAfinity/bio_rxiv__64898__2026__11__02__763650-299-18-22
Average 96 stars, based on 1 article reviews
antibodies against human cd45 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Proteintech coralite594 anti mouse cd45 antibody
The immune cells infiltration in TME of different therapy groups (A and B) Flow cytometry analysis and quantification of the percentage of M1-like macrophages in tumors (gate out of <t>CD45</t> + cells, mean ± SEM, n = 3). p values were analyzed by one-way ANOVA, ns, not significant; p > 0.05, ∗ p ≤ 0.05, ∗∗ p ≤ 0.01. (C and D) Flow cytometry analysis and quantification of the percentage of M2-like macrophages in tumors (gate out of CD45 + cells, mean ± SEM, n = 3). p values were analyzed by one-way ANOVA, ∗ p ≤ 0.05. (E and F) Flow cytometry analysis and quantification of the percentage of mature DCs in tumors (gate out of CD11c + cells, mean ± SEM, n = 3). p values were analyzed by one-way ANOVA, ∗ p ≤ 0.05, ∗∗ p ≤ 0.01, ∗∗∗ p ≤ 0.001. (G and H) Flow cytometry analysis and quantification of the percentage of CD8 + T cells in tumors (gate out of CD45 + cells, mean ± SEM, n = 3). p values were analyzed by one-way ANOVA, ∗∗∗∗ p ≤ 0.0001.
Coralite594 Anti Mouse Cd45 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd45+antibody/CD45+Antibody/pmc13755573-321-0-4
Average 96 stars, based on 1 article reviews
coralite594 anti mouse cd45 antibody - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

Image Search Results


Therapeutic effects on inflammatory cell infiltration. ( A ) Representative OCT images of the anterior chamber 10 days post-alkali burn, including healthy, alkali burn only (untreated), and treatment with aflibercept or anti–Scg3 hAb, respectively. ( B ) H&E images showing leukocyte infiltration ( red arrows ) in the corneas, day 10 post-injury ( n = 3 corneas). ( C , D ) Images showing flow cytometry data ( C ) and quantification of CD45 + cells ( D ) on day 3 after alkali burn ( n = 3 samples per group; 5 corneas pooled per sample). ( E , F ) Immunofluorescence images of corneas stained with anti-CD45 ( E ), and the quantified number of CD45 + cells ( F ) ( n = 3 corneas). Scale bar : 50 µm. ( G , H ) Graphs showing mRNA expression of IL-1α ( G ) and TGF-β ( H ) ( n = 3 samples per group; 5 corneas pooled per sample). Data are presented as ±SEM. P < 0.05 (one-way ANOVA).

Journal: Investigative Ophthalmology & Visual Science

Article Title: Subconjunctival Injection of Anti-Secretogranin III Mitigates Corneal Damage in Alkali Burn Injury Model

doi: 10.1167/iovs.67.13.15

Figure Lengend Snippet: Therapeutic effects on inflammatory cell infiltration. ( A ) Representative OCT images of the anterior chamber 10 days post-alkali burn, including healthy, alkali burn only (untreated), and treatment with aflibercept or anti–Scg3 hAb, respectively. ( B ) H&E images showing leukocyte infiltration ( red arrows ) in the corneas, day 10 post-injury ( n = 3 corneas). ( C , D ) Images showing flow cytometry data ( C ) and quantification of CD45 + cells ( D ) on day 3 after alkali burn ( n = 3 samples per group; 5 corneas pooled per sample). ( E , F ) Immunofluorescence images of corneas stained with anti-CD45 ( E ), and the quantified number of CD45 + cells ( F ) ( n = 3 corneas). Scale bar : 50 µm. ( G , H ) Graphs showing mRNA expression of IL-1α ( G ) and TGF-β ( H ) ( n = 3 samples per group; 5 corneas pooled per sample). Data are presented as ±SEM. P < 0.05 (one-way ANOVA).

Article Snippet: The slides were then incubated with primary antibodies, including anti–fibronectin (ab2413, 1:500 dilution; Abcam, Cambridge, UK), anti–α-smooth muscle actin (α-SMA; SC56495, 1:500 dilution; Santa Cruz Biotechnology, Dallas, TX, USA), or DyLight 650 conjugated anti-CD45 (NB100-77417, 1:500 dilution; Novus Biologicals, Centennial, CO, USA), at 4°C overnight.

Techniques: Flow Cytometry, Immunofluorescence, Staining, Expressing

Combination therapy activates innate immunity via the STING-TBK1-IRF3-IFNβ pathway and enhances T-cell function. (A) Western blot analysis of STING pathway components (TBK1, p-TBK1, p-IRF3, IFNβ, NF-κB) in H82R and H526R cells. (B) Schematic illustration of the multicellular tumor spheroid (MCT) model composed of H82R SCLC cells, MRC-5 fibroblasts, HUVECs, and PBMCs. (C) Representative bright-field images of MCTs after treatment. Scale bar, 100 μm. (D) Flow cytometry analysis of CD8 + cytotoxic T cells, CD4 + helper T cells, and CD45 + HLA-DR + activated immune cells in MCTs (left) and quantification of cell percentages (right). All experiments were performed independently three times. n = 3 biologically independent replicates. The Student’s t-test was used to estimate the significance of the difference between two groups. Comparisons among multiple groups were performed by one-way ANOVA followed by Tukey’s post hoc test. Data were presented as means ± s.d. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant.

Journal: Frontiers in Pharmacology

Article Title: Anlotinib suppresses homologous recombination via the E2F8-RAD51 axis to activate STING immunity and potentiate PARP inhibitor synthetic lethality in resistant small cell lung cancer

doi: 10.3389/fphar.2026.1939827

Figure Lengend Snippet: Combination therapy activates innate immunity via the STING-TBK1-IRF3-IFNβ pathway and enhances T-cell function. (A) Western blot analysis of STING pathway components (TBK1, p-TBK1, p-IRF3, IFNβ, NF-κB) in H82R and H526R cells. (B) Schematic illustration of the multicellular tumor spheroid (MCT) model composed of H82R SCLC cells, MRC-5 fibroblasts, HUVECs, and PBMCs. (C) Representative bright-field images of MCTs after treatment. Scale bar, 100 μm. (D) Flow cytometry analysis of CD8 + cytotoxic T cells, CD4 + helper T cells, and CD45 + HLA-DR + activated immune cells in MCTs (left) and quantification of cell percentages (right). All experiments were performed independently three times. n = 3 biologically independent replicates. The Student’s t-test was used to estimate the significance of the difference between two groups. Comparisons among multiple groups were performed by one-way ANOVA followed by Tukey’s post hoc test. Data were presented as means ± s.d. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant.

Article Snippet: After treatment, MCTs were dissociated into single cells and stained with fluorescently labeled antibodies against CD8 (E-AB-F1109C, Elabscience), CD4 (E-AB-F1110E, Elabscience), CD45 (E-AB-F1137F, Elabscience) and HLA-DR (E-AB-F1111D, Elabscience).

Techniques: Cell Function Assay, Western Blot, Analysis, Flow Cytometry

a. Leukemic burden in T-ALL PDX1 mice, measured as the percentage of human CD45-positive (hCD45⁺) cells in peripheral blood during treatment with ASNase (25 IU/mouse every 8 days) for 5 weeks. Treatment was discontinued following sacrifice of the vehicle-treated mice, and the remaining mice were monitored until reaching the experimental endpoint. Each dot represents an individual mouse. b. Bodyweight of mice shown in , expressed as the percentage of baseline bodyweight. Dots represent group means; error bars indicate SEM.

Journal: bioRxiv

Article Title: PERTURBATION OF THE AMINO ACID STRESS RESPONSE PATHWAY EXPOSES A METABOLIC VULNERABILITY IN MULTIPLE AGGRESSIVE CANCER SUBTYPES

doi: 10.64898/2026.11.02.763650

Figure Lengend Snippet: a. Leukemic burden in T-ALL PDX1 mice, measured as the percentage of human CD45-positive (hCD45⁺) cells in peripheral blood during treatment with ASNase (25 IU/mouse every 8 days) for 5 weeks. Treatment was discontinued following sacrifice of the vehicle-treated mice, and the remaining mice were monitored until reaching the experimental endpoint. Each dot represents an individual mouse. b. Bodyweight of mice shown in , expressed as the percentage of baseline bodyweight. Dots represent group means; error bars indicate SEM.

Article Snippet: Red blood cells were lysed using ACK lysis buffer (Gibco, #A1049201) , and remaining cells were stained using antibodies against human CD45 (Miltenyi Biotech, #130-110-632) or human CD19 (#12-0199-42).

Techniques:

a. Relative viability of leukemic cells isolated from mice treated with a single intravenous dose of ASNase (100 IU/mouse) or vehicle (n = 3 mice per group). Cells were treated ex vivo with a two-fold serial dilution of ASNase (maximum concentration 2000 mIU/mL) for 72 h before viability was assessed using CellTiter-Glo. Concentrations were log-transformed. Each dot represents the mean of three biological replicates; error bars indicate SD. b. Relative ASNS mRNA expression in leukemic cells isolated from mice in (a) treated with ASNase or vehicle. Error bars indicate SEM. **p = 0.0038 (unpaired two-tailed t-test). c. Relative ATF4 mRNA expression in leukemic cells isolated from mice in (a) treated with ASNase or vehicle. Error bars indicate SEM. *p = 0.0238 (unpaired two-tailed t-test). d. Automated capillary western blot (WES) showing ASNS protein expression in leukemic cells isolated from mice in a treated with ASNase or vehicle. β-Actin serves as the loading control. Each lane is a biological replicate. e. Leukemic burden in T-ALL PDX1 mice, measured as the percentage of human CD45-positive (hCD45⁺) cells in peripheral blood. Mice received vehicle, ASNase (25 IU/mouse, single dose; n = 3), GCN2-IN-6 (3 mg/kg, oral dose every 3.5 days; n = 3), or the combination (n = 3). No significant differences were observed between treatment groups before treatment (day 0). At day 7, all treatment groups showed reduced leukemic burden compared with vehicle (*p = 0.0300 for ASNase, **p = 0.0017 for GCN2-IN-6, ***p = 0.0009 for the combination; one-way ANOVA with Dunnett’s multiple-comparison correction). Dots represent group means; error bars indicate SEM.

Journal: bioRxiv

Article Title: PERTURBATION OF THE AMINO ACID STRESS RESPONSE PATHWAY EXPOSES A METABOLIC VULNERABILITY IN MULTIPLE AGGRESSIVE CANCER SUBTYPES

doi: 10.64898/2026.11.02.763650

Figure Lengend Snippet: a. Relative viability of leukemic cells isolated from mice treated with a single intravenous dose of ASNase (100 IU/mouse) or vehicle (n = 3 mice per group). Cells were treated ex vivo with a two-fold serial dilution of ASNase (maximum concentration 2000 mIU/mL) for 72 h before viability was assessed using CellTiter-Glo. Concentrations were log-transformed. Each dot represents the mean of three biological replicates; error bars indicate SD. b. Relative ASNS mRNA expression in leukemic cells isolated from mice in (a) treated with ASNase or vehicle. Error bars indicate SEM. **p = 0.0038 (unpaired two-tailed t-test). c. Relative ATF4 mRNA expression in leukemic cells isolated from mice in (a) treated with ASNase or vehicle. Error bars indicate SEM. *p = 0.0238 (unpaired two-tailed t-test). d. Automated capillary western blot (WES) showing ASNS protein expression in leukemic cells isolated from mice in a treated with ASNase or vehicle. β-Actin serves as the loading control. Each lane is a biological replicate. e. Leukemic burden in T-ALL PDX1 mice, measured as the percentage of human CD45-positive (hCD45⁺) cells in peripheral blood. Mice received vehicle, ASNase (25 IU/mouse, single dose; n = 3), GCN2-IN-6 (3 mg/kg, oral dose every 3.5 days; n = 3), or the combination (n = 3). No significant differences were observed between treatment groups before treatment (day 0). At day 7, all treatment groups showed reduced leukemic burden compared with vehicle (*p = 0.0300 for ASNase, **p = 0.0017 for GCN2-IN-6, ***p = 0.0009 for the combination; one-way ANOVA with Dunnett’s multiple-comparison correction). Dots represent group means; error bars indicate SEM.

Article Snippet: Red blood cells were lysed using ACK lysis buffer (Gibco, #A1049201) , and remaining cells were stained using antibodies against human CD45 (Miltenyi Biotech, #130-110-632) or human CD19 (#12-0199-42).

Techniques: Isolation, Ex Vivo, Serial Dilution, Concentration Assay, Transformation Assay, Expressing, Two Tailed Test, Automated, Western Blot, Control, Comparison

a-d. Leukemic burden, measured as the percentage of human CD45-positive (hCD45⁺) cells in peripheral blood, in T-ALL PDX models 1–4 treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 6 mice per group). Treatment was discontinued once vehicle-treated mice reached the experimental endpoint, and the remaining mice were monitored for survival. Survival was analyzed using the Kaplan-Meier method with log-rank (Mantel-Cox) testing. Significance is indicated in the figure. e-f. Leukemic burden, measured as the percentage of human CD19-positive (hCD19⁺) cells in peripheral blood, in B-ALL PDX models 1 and 2 treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 6 mice per group). Treatment was discontinued once vehicle-treated mice reached the experimental endpoint, and the remaining mice were monitored for survival. Survival was analyzed using the Kaplan-Meier method with log-rank (Mantel-Cox) testing. Significance is indicated in the figure. g. Spleen weight of AML PDX-bearing mice treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 7 mice per group). Spleens were collected at the experimental endpoint. Statistical significance was determined using the Kruskal-Wallis test. **p = 0.0012. h. Leukemic burden, measured as the percentage of hCD45⁺ cells in peripheral blood, in the AML PDX model following treatment with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 7 mice per group). Statistical analysis was performed using a linear mixed-effects model (REML) with time and treatment as fixed effects. *p = 0.0325. i. Relative tumor growth of an ovarian cancer cell line-derived xenograft (CDX) treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 6 mice per group). Statistical analysis was performed using a linear mixed-effects model (REML). ***p = 0.0008 j. Tumor volume of a neuroblastoma PDX treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 4 per group). Statistical analysis was performed using a linear mixed-effects model (REML). ***p = 0.0002. k – n. Relative tumor growth of four TNBC PDX models treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 5 mice per group). Dots represent group means; error bars indicate SEM. Statistical analysis was performed using a linear mixed-effects model (REML). Significance is indicated in the figure.

Journal: bioRxiv

Article Title: PERTURBATION OF THE AMINO ACID STRESS RESPONSE PATHWAY EXPOSES A METABOLIC VULNERABILITY IN MULTIPLE AGGRESSIVE CANCER SUBTYPES

doi: 10.64898/2026.11.02.763650

Figure Lengend Snippet: a-d. Leukemic burden, measured as the percentage of human CD45-positive (hCD45⁺) cells in peripheral blood, in T-ALL PDX models 1–4 treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 6 mice per group). Treatment was discontinued once vehicle-treated mice reached the experimental endpoint, and the remaining mice were monitored for survival. Survival was analyzed using the Kaplan-Meier method with log-rank (Mantel-Cox) testing. Significance is indicated in the figure. e-f. Leukemic burden, measured as the percentage of human CD19-positive (hCD19⁺) cells in peripheral blood, in B-ALL PDX models 1 and 2 treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 6 mice per group). Treatment was discontinued once vehicle-treated mice reached the experimental endpoint, and the remaining mice were monitored for survival. Survival was analyzed using the Kaplan-Meier method with log-rank (Mantel-Cox) testing. Significance is indicated in the figure. g. Spleen weight of AML PDX-bearing mice treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 7 mice per group). Spleens were collected at the experimental endpoint. Statistical significance was determined using the Kruskal-Wallis test. **p = 0.0012. h. Leukemic burden, measured as the percentage of hCD45⁺ cells in peripheral blood, in the AML PDX model following treatment with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 7 mice per group). Statistical analysis was performed using a linear mixed-effects model (REML) with time and treatment as fixed effects. *p = 0.0325. i. Relative tumor growth of an ovarian cancer cell line-derived xenograft (CDX) treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 6 mice per group). Statistical analysis was performed using a linear mixed-effects model (REML). ***p = 0.0008 j. Tumor volume of a neuroblastoma PDX treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 4 per group). Statistical analysis was performed using a linear mixed-effects model (REML). ***p = 0.0002. k – n. Relative tumor growth of four TNBC PDX models treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 5 mice per group). Dots represent group means; error bars indicate SEM. Statistical analysis was performed using a linear mixed-effects model (REML). Significance is indicated in the figure.

Article Snippet: Red blood cells were lysed using ACK lysis buffer (Gibco, #A1049201) , and remaining cells were stained using antibodies against human CD45 (Miltenyi Biotech, #130-110-632) or human CD19 (#12-0199-42).

Techniques: Analysis, Derivative Assay, Xenograft Assay

The immune cells infiltration in TME of different therapy groups (A and B) Flow cytometry analysis and quantification of the percentage of M1-like macrophages in tumors (gate out of CD45 + cells, mean ± SEM, n = 3). p values were analyzed by one-way ANOVA, ns, not significant; p > 0.05, ∗ p ≤ 0.05, ∗∗ p ≤ 0.01. (C and D) Flow cytometry analysis and quantification of the percentage of M2-like macrophages in tumors (gate out of CD45 + cells, mean ± SEM, n = 3). p values were analyzed by one-way ANOVA, ∗ p ≤ 0.05. (E and F) Flow cytometry analysis and quantification of the percentage of mature DCs in tumors (gate out of CD11c + cells, mean ± SEM, n = 3). p values were analyzed by one-way ANOVA, ∗ p ≤ 0.05, ∗∗ p ≤ 0.01, ∗∗∗ p ≤ 0.001. (G and H) Flow cytometry analysis and quantification of the percentage of CD8 + T cells in tumors (gate out of CD45 + cells, mean ± SEM, n = 3). p values were analyzed by one-way ANOVA, ∗∗∗∗ p ≤ 0.0001.

Journal: iScience

Article Title: In situ -activated engineered bacteria release combined dual-therapeutic proteins for tumor immunotherapy

doi: 10.1016/j.isci.2026.118090

Figure Lengend Snippet: The immune cells infiltration in TME of different therapy groups (A and B) Flow cytometry analysis and quantification of the percentage of M1-like macrophages in tumors (gate out of CD45 + cells, mean ± SEM, n = 3). p values were analyzed by one-way ANOVA, ns, not significant; p > 0.05, ∗ p ≤ 0.05, ∗∗ p ≤ 0.01. (C and D) Flow cytometry analysis and quantification of the percentage of M2-like macrophages in tumors (gate out of CD45 + cells, mean ± SEM, n = 3). p values were analyzed by one-way ANOVA, ∗ p ≤ 0.05. (E and F) Flow cytometry analysis and quantification of the percentage of mature DCs in tumors (gate out of CD11c + cells, mean ± SEM, n = 3). p values were analyzed by one-way ANOVA, ∗ p ≤ 0.05, ∗∗ p ≤ 0.01, ∗∗∗ p ≤ 0.001. (G and H) Flow cytometry analysis and quantification of the percentage of CD8 + T cells in tumors (gate out of CD45 + cells, mean ± SEM, n = 3). p values were analyzed by one-way ANOVA, ∗∗∗∗ p ≤ 0.0001.

Article Snippet: CoraLite594 anti-mouse CD45 antibody (Proteintech, CL594-65087), eFluor 450 anti-F4/80 antibody (Biolegend, 48–4801-82), APC-Cyanine7 anti-mouse CD11b antibody (Proteintech, AY7-65055), PE anti-CD86 antibody (Proteintech, PE-65068) and FITC anti-CD80 antibody (Proteintech, FITC-65076) are to determine the M1 type macrophages; CoraLite594 anti-mouse CD45 antibody (Proteintech, CL594-65087), eFluor 450 anti-F4/80 antibody (Biolegend, 48-4801-82), APC-Cyanine7 anti-mouse CD11b antibody (Proteintech, AY7-65055), APC anti-mouse CD206 antibody (Biolegend, 17-2061-82) are to characterize M2 type macrophages; CoraLite594 anti-mouse CD45 antibody (Proteintech, CL594-65087), APC anti-mouse CD11c antibody (Proteintech, APC-65130), PE anti-CD86 antibody (Proteintech, PE-65068) and FITC anti-CD80 antibody (Proteintech, FITC-65076) are to characterize dendritic cells (DCs); CoraLite594 anti-mouse CD45 antibody (Proteintech, CL594-65087), FITC anti-mouse CD3 antibody (Proteintech, CL488-65077), APC-Cyanine7 anti-mouse CD8 (Proteintech, AY7-FcA98472-2) are to characterize CD8 + T cells.

Techniques: Flow Cytometry, Analysis

Journal: iScience

Article Title: In situ -activated engineered bacteria release combined dual-therapeutic proteins for tumor immunotherapy

doi: 10.1016/j.isci.2026.118090

Figure Lengend Snippet:

Article Snippet: CoraLite594 anti-mouse CD45 antibody (Proteintech, CL594-65087), eFluor 450 anti-F4/80 antibody (Biolegend, 48–4801-82), APC-Cyanine7 anti-mouse CD11b antibody (Proteintech, AY7-65055), PE anti-CD86 antibody (Proteintech, PE-65068) and FITC anti-CD80 antibody (Proteintech, FITC-65076) are to determine the M1 type macrophages; CoraLite594 anti-mouse CD45 antibody (Proteintech, CL594-65087), eFluor 450 anti-F4/80 antibody (Biolegend, 48-4801-82), APC-Cyanine7 anti-mouse CD11b antibody (Proteintech, AY7-65055), APC anti-mouse CD206 antibody (Biolegend, 17-2061-82) are to characterize M2 type macrophages; CoraLite594 anti-mouse CD45 antibody (Proteintech, CL594-65087), APC anti-mouse CD11c antibody (Proteintech, APC-65130), PE anti-CD86 antibody (Proteintech, PE-65068) and FITC anti-CD80 antibody (Proteintech, FITC-65076) are to characterize dendritic cells (DCs); CoraLite594 anti-mouse CD45 antibody (Proteintech, CL594-65087), FITC anti-mouse CD3 antibody (Proteintech, CL488-65077), APC-Cyanine7 anti-mouse CD8 (Proteintech, AY7-FcA98472-2) are to characterize CD8 + T cells.

Techniques: